Skip to main content
Premium Trial:

Request an Annual Quote

Medvet, Agendia, NIDA, European Union

Premium
Medvet to Distribute Agendia's MammaPrint Test in Australia
 
Medvet Science will distribute Agendia’s MammaPrint breast cancer prognosis test to hospitals in Australia, Agendia said this week.
 
The Dutch company originally launched the microarray-based test, developed from a 70-gene tumor expression profile that predicts disease outcome, in December 2004 (see BAN 12/14/2004). The test is designed to guide physicians in planning therapy following initial breast cancer treatment.
 
Agendia CEO Bernhard Sixt said the Australia agreement is part of the company’s planned global expansion for the test. Medvet also has agreements in place with companies to market the test in South America, the UK, and South Africa. 
 

 
NIDA Seeks Recommendations on SNPs to Develop 'Neuroarray' Platform
 
The National Institute of Drug Abuse is seeking nominations for SNPs to include in a custom microarray platform it is designing to study the genetics and pharmacogenetics of drug abuse, addiction, and related mental disorders.
 
In a request for information released last week, NIDA said that it plans to develop the so-called Neuroarray “pending availability of funds,” and that it is looking for community input on “custom SNPs that provide in-depth coverage of genes with prior knowledge of association with drug addiction and related disorders.”
 
NIDA said it intends to make the array available competitively through standard NIH mechanisms to help researchers study genetic vulnerability to addiction and related disorders, and to develop genetic patient profiles for targeted drugs.
 
The deadline for responses is March 30. Nominations for SNPs can be submitted here.
 

 
EU Sets Aside $650K to Hold Five Genomics Conferences in Europe
 
The European Union has granted €500,000 ($650,000) to fund a series of conferences this year about genomics and disease, the Cancer Research Center at the University of Edinburgh said last week.
 
The funding will be used by the Marie Curie Genomic Architecture in Relation to Disease program to hold three conferences and two workshops, including one specifically focused on array technology, between April and September.
 
The CRC said the events will consider how data from studies such as large-scale SNP projects and large-scale DNA-sequencing analysis and fields such as bioinformatics are used in an interdisciplinary manner in disease research. 
  • The “Molecular Profiling of the Genome” conference will be held in Amsterdam, the Netherlands, May 2-5;
  • The “Interplay Between Genetics and Epigenetics” conference will be held in Madrid, Spain, May 2-4; 
  • The “Higher Order Genome Architecture” conference will be held in Edinburgh, Scotland, April 25-27; 
  • The “Array Techniques to Identify Copy Number Variations” workshop will be held in Helsinki, Finland, Sept. 11-15; and 
  • The “Genome Bioinformatic Techniques” workshop will be held in Braga, Portugal, Sep. 9-13
More information is available at the MCGARD website.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.